ES2798598T3 - Tratamiento combinado con un agonista de TLR7 y un inhibidor de ensamblaje de la cápside del VHB - Google Patents
Tratamiento combinado con un agonista de TLR7 y un inhibidor de ensamblaje de la cápside del VHB Download PDFInfo
- Publication number
- ES2798598T3 ES2798598T3 ES16710952T ES16710952T ES2798598T3 ES 2798598 T3 ES2798598 T3 ES 2798598T3 ES 16710952 T ES16710952 T ES 16710952T ES 16710952 T ES16710952 T ES 16710952T ES 2798598 T3 ES2798598 T3 ES 2798598T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- methyl
- oxo
- acid
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCOC(C1=C(CN(CC2)C[C@@](C*3CC(C)(C)C(O)=O)N2C3=O)NC(C2=SC=C*2)=N[C@]1Cc1cccc(F)c1C)=O Chemical compound CCOC(C1=C(CN(CC2)C[C@@](C*3CC(C)(C)C(O)=O)N2C3=O)NC(C2=SC=C*2)=N[C@]1Cc1cccc(F)c1C)=O 0.000 description 8
- IZCMCSPPLIGLOB-MSSCULAGSA-N CCOC(C1=C(CC(CCC[C@H]2CN3CC(C)(C)C(O)=O)CCCC2C3=O)NC(c2ncc[s]2)=NC1c1cccc(F)c1C)=O Chemical compound CCOC(C1=C(CC(CCC[C@H]2CN3CC(C)(C)C(O)=O)CCCC2C3=O)NC(c2ncc[s]2)=NC1c1cccc(F)c1C)=O IZCMCSPPLIGLOB-MSSCULAGSA-N 0.000 description 1
- VPBBBJPYQHQRGK-LYFYHCNISA-N CC[C@@H]([C@H](CC1)O[C@H]1N(C(N=C(N)NC1=O)=C1S1)C1=O)O Chemical compound CC[C@@H]([C@H](CC1)O[C@H]1N(C(N=C(N)NC1=O)=C1S1)C1=O)O VPBBBJPYQHQRGK-LYFYHCNISA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2015074269 | 2015-03-16 | ||
CN2015074854 | 2015-03-23 | ||
CN2015084480 | 2015-07-20 | ||
CN2016074012 | 2016-02-18 | ||
PCT/EP2016/055484 WO2016146598A1 (en) | 2015-03-16 | 2016-03-15 | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2798598T3 true ES2798598T3 (es) | 2020-12-11 |
Family
ID=55587263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES16710952T Active ES2798598T3 (es) | 2015-03-16 | 2016-03-15 | Tratamiento combinado con un agonista de TLR7 y un inhibidor de ensamblaje de la cápside del VHB |
Country Status (27)
Country | Link |
---|---|
US (1) | US11771699B2 (ja) |
EP (3) | EP3845227A1 (ja) |
JP (3) | JP6667547B2 (ja) |
KR (4) | KR20170113658A (ja) |
CN (1) | CN107427514B (ja) |
AU (3) | AU2016232353B2 (ja) |
CA (1) | CA2979490C (ja) |
CL (1) | CL2017002230A1 (ja) |
CR (1) | CR20170424A (ja) |
DK (1) | DK3270915T3 (ja) |
ES (1) | ES2798598T3 (ja) |
HK (1) | HK1245082A1 (ja) |
HR (1) | HRP20200943T1 (ja) |
HU (1) | HUE050736T2 (ja) |
IL (3) | IL253493B (ja) |
MA (2) | MA55581A (ja) |
MX (2) | MX370769B (ja) |
MY (1) | MY190603A (ja) |
PE (2) | PE20171648A1 (ja) |
PL (1) | PL3270915T3 (ja) |
PT (1) | PT3270915T (ja) |
RS (1) | RS60350B1 (ja) |
RU (1) | RU2718917C2 (ja) |
SG (2) | SG11201706835WA (ja) |
SI (1) | SI3270915T1 (ja) |
UA (1) | UA123670C2 (ja) |
WO (1) | WO2016146598A1 (ja) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3114128T (lt) * | 2014-03-07 | 2019-03-25 | F. Hoffmann-La Roche Ag | Nauji 6 padėtyje kondensuoti heteroarildihidropirimidinai, skirti hepatito b virusinės infekcijos gydymui ir profilaktikai |
CA2963717C (en) | 2014-12-08 | 2023-10-10 | F. Hoffmann-La Roche Ag | 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection |
CN107427514B (zh) | 2015-03-16 | 2021-07-13 | 豪夫迈·罗氏有限公司 | 使用tlr7激动剂和hbv衣壳装配抑制剂的组合治疗 |
CN107592864B (zh) * | 2015-05-12 | 2021-04-16 | 豪夫迈·罗氏有限公司 | 用于治疗和预防病毒感染的新的取代的氨基噻唑并嘧啶二酮 |
BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
WO2017211791A1 (en) * | 2016-06-07 | 2017-12-14 | F. Hoffmann-La Roche Ag | Combination therapy of an hbsag inhibitor and a tlr7 agonist |
EP3970750A1 (en) * | 2016-09-13 | 2022-03-23 | F. Hoffmann-La Roche AG | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor |
US11230559B2 (en) * | 2017-01-06 | 2022-01-25 | Hoffmann-La Roche Inc. | Solid forms of [(1 S)-1 -[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-D]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-Yl]proptl] acetate |
WO2018127525A1 (en) * | 2017-01-06 | 2018-07-12 | F. Hoffmann-La Roche Ag | PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED 5-AMINO-6H-THIAZOLO[4,5-d]PYRIMIDINE-2,7-DIONE COMPOUNDS |
JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
AU2018290511B2 (en) | 2017-06-26 | 2022-01-27 | Sunshine Lake Pharma Co., Ltd. | Dihydropyrimidine compounds and uses thereof in medicine |
WO2019001420A1 (en) | 2017-06-27 | 2019-01-03 | Janssen Pharmaceutica Nv | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING INFECTIONS WITH HEPATITIS B VIRUS |
CN109678859B (zh) * | 2017-10-18 | 2020-12-29 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
EP3704127A1 (en) | 2017-11-02 | 2020-09-09 | AiCuris GmbH & Co. KG | Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv) |
CU20200045A7 (es) | 2017-11-02 | 2021-03-11 | Aicuris Gmbh & Co Kg | Derivados de indol-2-carboxamidas sustituidos con pirazolo-piperidina activos contra el virus de la hepatitis b (vhb) |
US11053235B2 (en) | 2018-08-09 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases |
UY38439A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Novedosas urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb) |
AR117188A1 (es) | 2018-11-02 | 2021-07-21 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb) |
UY38435A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb) |
UY38434A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv) |
AR116947A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
CA3118339A1 (en) | 2018-11-02 | 2020-05-07 | Aicuris Gmbh & Co. Kg | Novel urea 6,7-dihydro-4h-thiazolo[5,4-c]pyridines active against the hepatitis b virus (hbv) |
JP2022514470A (ja) * | 2018-12-14 | 2022-02-14 | エフ.ホフマン-ラ ロシュ アーゲー | B型肝炎ウイルス感染症を治療および予防するためのクロマン-4-オン誘導体 |
TW202035412A (zh) * | 2018-12-20 | 2020-10-01 | 比利時商健生藥品公司 | 雜芳基二氫嘧啶衍生物和治療b型肝炎感染之方法 |
KR20210106421A (ko) * | 2018-12-20 | 2021-08-30 | 얀센 파마슈티카 엔.브이. | 헤테로아릴디히드로피리미딘 유도체 및 b형 간염 감염의 치료 방법 |
BR112021019054A2 (pt) | 2019-03-25 | 2021-11-30 | F Hoffmann La Roche Ag | Formas sólidas de um composto do modificador alostérico da proteína do núcleo do vhb |
CN113748113A (zh) | 2019-04-30 | 2021-12-03 | 艾库里斯有限及两合公司 | 具有抗乙型肝炎病毒(hbv)活性的新型吲哚嗪-2-甲酰胺类化合物 |
US20220227785A1 (en) | 2019-04-30 | 2022-07-21 | Aicuris Gmbh & Co. Kg | Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv) |
CU20210088A7 (es) | 2019-04-30 | 2022-06-06 | Aicuris Gmbh & Co Kg | Compuestos derivados sustituidos de indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
JP2022533008A (ja) | 2019-04-30 | 2022-07-21 | アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | B型肝炎ウイルス(hbv)に対し活性な新規のオキサリルピペラジン |
WO2020255017A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
CA3146992A1 (en) * | 2019-07-31 | 2021-02-04 | Janssen Sciences Ireland Unlimited Company | Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases |
CR20220282A (es) | 2019-11-26 | 2022-11-28 | Primmune Therapeutics Inc | Agonistas del tlr7 |
TW202137987A (zh) * | 2019-12-24 | 2021-10-16 | 瑞士商赫孚孟拉羅股份公司 | 用於治療hbv之靶向hbv的治療性寡核苷酸及tlr7促效劑之醫藥組合 |
AU2020415307A1 (en) * | 2019-12-24 | 2022-06-09 | F. Hoffmann-La Roche Ag | Method of treating virus infection using a TLR7 agonist |
JP2023520480A (ja) * | 2020-04-02 | 2023-05-17 | サウザーン リサーチ インスチチュート | アルファウイルスに対する強力な抗ウイルス剤としての新規2-ピリミドン類似体 |
JP2023536999A (ja) | 2020-08-05 | 2023-08-30 | エフ. ホフマン-ラ ロシュ アーゲー | B型肝炎患者のオリゴヌクレオチド処置 |
WO2022121844A1 (zh) * | 2020-12-09 | 2022-06-16 | 上海维申医药有限公司 | 一种二氢嘧啶类化合物、其制备方法及应用 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5476659A (en) | 1982-11-09 | 1995-12-19 | The Scripps Research Institute | Cancerous B cell treatment using substituted nucleoside derivatives |
US5166141A (en) | 1983-11-01 | 1992-11-24 | Scripps Clinic And Research Foundation | Immunostimulating 7-deaza-7-oxa- and 7-deaza-7-oxo-analogs of 8-substituted-guanine-9-(1'-beta-D-aldoglycosidyl) derivatives and methods of treating test animals |
US5041426A (en) | 1987-12-21 | 1991-08-20 | Brigham Young University | Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides |
EP1072607A3 (en) | 1996-10-16 | 2001-09-12 | ICN Pharmaceuticals, Inc. | Purine L-nucleosides, analogs and uses therof |
KR100412480B1 (ko) | 1996-10-16 | 2003-12-31 | 아이씨엔 파마슈티컬스, 인코포레이티드 | 푸린 l-누클레오시드, 이의 유사체 및 이들의 용도 |
DE10012549A1 (de) | 2000-03-15 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
DE10012824A1 (de) | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
DE10013126A1 (de) | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
WO2005016235A2 (en) | 2003-04-14 | 2005-02-24 | The Regents Of The University Of California | Combined use of impdh inhibitors with toll-like receptor agonists |
AU2004268616B2 (en) | 2003-08-25 | 2010-10-07 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
OA13310A (en) | 2003-09-05 | 2007-04-13 | Anadys Pharmaceuticals Inc | TLR7 ligands for the treatment of hepatitis C. |
DE602004014628D1 (de) * | 2003-10-01 | 2008-08-07 | Nycomed Gmbh | Imidazopyridin-derivate und ihre verwendung als induzierbare no-synthase inhibitoren |
CN1926241A (zh) | 2004-02-27 | 2007-03-07 | 帝斯曼知识产权资产管理有限公司 | 用酶来制备对映异构体富集的β-2-氨基酸的方法 |
CA2574090A1 (en) | 2004-07-18 | 2006-12-21 | Coley Pharmaceutical Group, Ltd. | Methods and compositions for inducing innate immune responses |
WO2006033995A2 (en) | 2004-09-16 | 2006-03-30 | Valeant Research And Development | Thiazolidin-4-ones having anti-hepatitis b activity |
JP2006088985A (ja) * | 2004-09-27 | 2006-04-06 | Toyoda Gosei Co Ltd | 頭部保護エアバッグ装置 |
WO2006054129A1 (en) | 2004-11-19 | 2006-05-26 | Institut Gustave Roussy | Improved treatment of cancer by double-stranded rna |
CN101212968B (zh) * | 2004-12-17 | 2011-11-16 | 安那迪斯药品股份有限公司 | 3,5-二取代的和3,5,7-三取代的-3H-噁唑并以及3H-噻唑并[4,5-d]嘧啶-2-酮化合物及其前药 |
ES2525567T3 (es) * | 2004-12-17 | 2014-12-26 | Anadys Pharmaceuticals, Inc. | Compuestos de 3H-oxazolo y 3H-tiazolo[4,5-d]pirimidin-2-ona 3,5-disustituidos y 3,5,7-trisustituidos y profármacos de los mismos |
US20090305382A1 (en) | 2005-09-22 | 2009-12-10 | The Scripps Research Institute | Alkoxy indolinone based protein kinase inhibitors |
WO2007056527A2 (en) | 2005-11-09 | 2007-05-18 | Cheng Si Yuan (China-International) Hepatitis Research Foundation | Diagnostic and therapeutic methods and agents |
AR061024A1 (es) | 2006-05-22 | 2008-07-30 | Novartis Ag | Maleato de 5-amino-3- (2'3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d] pirimidin-2-ona. |
US20080026986A1 (en) | 2006-06-05 | 2008-01-31 | Rong-Fu Wang | Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling |
CA2655904C (en) | 2006-06-22 | 2014-11-18 | Anadys Pharmaceuticals, Inc. | Prodrugs of 5-amino-3-(3'-deoxy-.beta.-d-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione |
EP2040712B1 (en) | 2006-07-18 | 2011-03-02 | Anadys Pharmaceuticals, Inc. | Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines |
BRPI0717741A2 (pt) | 2006-10-17 | 2014-04-08 | Anadys Pharmaceuticals Inc | Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença |
GB0701366D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
WO2009026292A1 (en) * | 2007-08-20 | 2009-02-26 | Anadys Pharmaceuticals, Inc. | Dosing methods for treating disease |
US20090291938A1 (en) | 2007-11-19 | 2009-11-26 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
PL2098526T3 (pl) | 2008-02-22 | 2014-06-30 | Neurotune Ag | Bicykliczne związki zawierające azot aktywne w stanach przewlekłego bólu |
DE102008027648A1 (de) | 2008-06-10 | 2009-12-17 | Schaeffler Kg | Spannvorrichtung |
US8470823B2 (en) | 2008-08-29 | 2013-06-25 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. | Saturated bicyclic heterocyclic derivatives as SMO antagonists |
WO2010069147A1 (zh) | 2008-12-17 | 2010-06-24 | 张中能 | 二氢嘧啶类化合物、其组合物及其应用 |
CN102372706A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
US20140050780A1 (en) | 2010-12-23 | 2014-02-20 | Ludwig Institute For Cancer Research Ltd. | Liposomal formulation of nonglycosidic ceramides and uses thereof |
US20140336159A1 (en) | 2011-10-07 | 2014-11-13 | Pulmatrix, Inc. | Methods for treating and diagnosing respiratory tract infections |
ES2649410T3 (es) * | 2011-12-21 | 2018-01-11 | Novira Therapeutics Inc. | Agentes antivirales para la hepatitis B |
CN103626752B (zh) * | 2012-08-24 | 2015-08-12 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
EP2892893B2 (en) * | 2012-09-10 | 2019-10-16 | F.Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
US8993771B2 (en) * | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
EA201592126A1 (ru) * | 2013-05-17 | 2016-05-31 | Ф. Хоффманн-Ля Рош Аг | 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b |
CN104650069B (zh) | 2013-11-19 | 2019-04-19 | 广东东阳光药业有限公司 | 4-甲基二氢嘧啶类化合物及其在药物中的应用 |
US10040818B2 (en) * | 2014-02-21 | 2018-08-07 | Vibrant Holdings, Llc | Selective photoactivation of amino acids for single step peptide coupling |
LT3114128T (lt) * | 2014-03-07 | 2019-03-25 | F. Hoffmann-La Roche Ag | Nauji 6 padėtyje kondensuoti heteroarildihidropirimidinai, skirti hepatito b virusinės infekcijos gydymui ir profilaktikai |
US20170266197A1 (en) | 2014-05-09 | 2017-09-21 | Indiana University Research And Technology Corporation | Methods and compositions for treating hepatitis b virus infections |
CA2963717C (en) * | 2014-12-08 | 2023-10-10 | F. Hoffmann-La Roche Ag | 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection |
CN107427514B (zh) | 2015-03-16 | 2021-07-13 | 豪夫迈·罗氏有限公司 | 使用tlr7激动剂和hbv衣壳装配抑制剂的组合治疗 |
AU2016349685A1 (en) * | 2015-11-03 | 2018-03-15 | F. Hoffmann-La Roche Ag | Combination therapy of an HBV capsid assembly inhibitor and an interferon |
EP3970750A1 (en) | 2016-09-13 | 2022-03-23 | F. Hoffmann-La Roche AG | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor |
-
2016
- 2016-03-15 CN CN201680016096.8A patent/CN107427514B/zh active Active
- 2016-03-15 WO PCT/EP2016/055484 patent/WO2016146598A1/en active Application Filing
- 2016-03-15 RU RU2017135467A patent/RU2718917C2/ru active
- 2016-03-15 MA MA055581A patent/MA55581A/fr unknown
- 2016-03-15 KR KR1020177025146A patent/KR20170113658A/ko not_active IP Right Cessation
- 2016-03-15 PT PT167109529T patent/PT3270915T/pt unknown
- 2016-03-15 KR KR1020227003346A patent/KR20220020412A/ko not_active Application Discontinuation
- 2016-03-15 EP EP20199071.0A patent/EP3845227A1/en not_active Withdrawn
- 2016-03-15 PL PL16710952T patent/PL3270915T3/pl unknown
- 2016-03-15 AU AU2016232353A patent/AU2016232353B2/en active Active
- 2016-03-15 UA UAA201709826A patent/UA123670C2/uk unknown
- 2016-03-15 MY MYPI2017703395A patent/MY190603A/en unknown
- 2016-03-15 PE PE2017001480A patent/PE20171648A1/es unknown
- 2016-03-15 MA MA052701A patent/MA52701A/fr unknown
- 2016-03-15 EP EP16710952.9A patent/EP3270915B1/en active Active
- 2016-03-15 HU HUE16710952A patent/HUE050736T2/hu unknown
- 2016-03-15 CA CA2979490A patent/CA2979490C/en active Active
- 2016-03-15 EP EP19208864.9A patent/EP3695837A1/en active Pending
- 2016-03-15 PE PE2021000460A patent/PE20211647A1/es unknown
- 2016-03-15 CR CR20170424A patent/CR20170424A/es unknown
- 2016-03-15 JP JP2017549086A patent/JP6667547B2/ja active Active
- 2016-03-15 SG SG11201706835WA patent/SG11201706835WA/en unknown
- 2016-03-15 MX MX2017011488A patent/MX370769B/es active IP Right Grant
- 2016-03-15 KR KR1020207021454A patent/KR102359212B1/ko active IP Right Grant
- 2016-03-15 DK DK16710952.9T patent/DK3270915T3/da active
- 2016-03-15 SI SI201630807T patent/SI3270915T1/sl unknown
- 2016-03-15 KR KR1020197020088A patent/KR102139708B1/ko active Application Filing
- 2016-03-15 RS RS20200644A patent/RS60350B1/sr unknown
- 2016-03-15 ES ES16710952T patent/ES2798598T3/es active Active
- 2016-03-15 SG SG10201912847QA patent/SG10201912847QA/en unknown
-
2017
- 2017-07-16 IL IL253493A patent/IL253493B/en active IP Right Grant
- 2017-09-04 CL CL2017002230A patent/CL2017002230A1/es unknown
- 2017-09-07 MX MX2022011756A patent/MX2022011756A/es unknown
- 2017-09-15 US US15/705,577 patent/US11771699B2/en active Active
-
2018
- 2018-04-03 HK HK18104431.9A patent/HK1245082A1/zh unknown
-
2019
- 2019-04-29 AU AU2019202966A patent/AU2019202966B2/en active Active
-
2020
- 2020-02-25 JP JP2020029017A patent/JP6859468B2/ja active Active
- 2020-06-12 HR HRP20200943TT patent/HRP20200943T1/hr unknown
- 2020-08-23 IL IL276865A patent/IL276865B/en active IP Right Grant
-
2021
- 2021-03-25 JP JP2021051550A patent/JP7195360B2/ja active Active
- 2021-04-07 AU AU2021202122A patent/AU2021202122A1/en active Pending
- 2021-04-27 IL IL282706A patent/IL282706A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2798598T3 (es) | Tratamiento combinado con un agonista de TLR7 y un inhibidor de ensamblaje de la cápside del VHB | |
WO2017211791A1 (en) | Combination therapy of an hbsag inhibitor and a tlr7 agonist | |
JP7101663B2 (ja) | Tlr7アゴニストとhbvキャプシドアセンブリ阻害剤の併用療法 | |
JP2019524684A (ja) | ジアゼピノン誘導体及びb型肝炎感染症の治療におけるその使用 | |
CA3146997A1 (en) | Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases | |
BR122021002683B1 (pt) | Tratamento combinado com um agonista de tlr7 e um inibidor de montagem de capsídeo de hbv | |
BR112017019758B1 (pt) | Tratamento combinado com um agonista de tlr7 e um inibidor de montagem de capsídeo de hbv | |
NZ733805B2 (en) | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor | |
WO2022257942A1 (en) | Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases | |
AU2020321067A1 (en) | Dihydropyrimidine derivatives and uses thereof in the treatment of HBV infection or of HBV-induced diseases | |
KR20220015421A (ko) | Hbv 캡시드 조립 조절제로서의 아제핀 | |
CN114555608A (zh) | 草酰胺取代的乙型肝炎病毒三环抑制剂 |